Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection.
Exp Hematol Oncol
; 11(1): 53, 2022 Sep 09.
Article
in English
| MEDLINE | ID: covidwho-2021341
ABSTRACT
Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to viral escape phenomena. Highly efficacious antiviral therapies in immunosuppressed hosts with COVID-19 are urgently needed. From February 2022, we introduced novel treatment combining antiviral therapies and neutralizing antibodies with frequent monitoring of spike-specific antibody and RT-PCR cycle threshold (Ct) values as indicators of viral load for immunocompromised patients with persistent COVID-19 infection. We applied this treatment to 10 immunosuppressed patients with COVID-19, and all completed treatment without relapse of infection. This may be a potentially successful treatment strategy that enables us to sustain viral clearance, determine optimal timing to stop treatment, and prevent virus reactivation in immunocompromised patients with persistent COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Long Covid
Language:
English
Journal:
Exp Hematol Oncol
Year:
2022
Document Type:
Article
Affiliation country:
S40164-022-00307-9
Similar
MEDLINE
...
LILACS
LIS